Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Total Liabilities: 2023-2025

Historic Total Liabilities for Immunome (IMNM) over the last 3 years, with Sep 2025 value amounting to $35.5 million.

  • Immunome's Total Liabilities fell 15.56% to $35.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.5 million, marking a year-over-year decrease of 15.56%. This contributed to the annual value of $59.1 million for FY2024, which is 106.14% up from last year.
  • Immunome's Total Liabilities amounted to $35.5 million in Q3 2025, which was up 31.23% from $27.0 million recorded in Q2 2025.
  • Immunome's Total Liabilities' 5-year high stood at $87.1 million during Q3 2023, with a 5-year trough of $27.0 million in Q2 2025.
  • In the last 3 years, Immunome's Total Liabilities had a median value of $35.5 million in 2025 and averaged $41.6 million.
  • Over the last 5 years, Immunome's Total Liabilities had its largest YoY gain of 106.14% in 2024, and its largest YoY loss of 51.78% in 2024.
  • Over the past 3 years, Immunome's Total Liabilities (Quarterly) stood at $28.7 million in 2023, then skyrocketed by 106.14% to $59.1 million in 2024, then dropped by 15.56% to $35.5 million in 2025.
  • Its Total Liabilities stands at $35.5 million for Q3 2025, versus $27.0 million for Q2 2025 and $35.6 million for Q1 2025.